A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

Also called NCT01316107

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01316107
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01316107. Allocation not applicable; no masking; primary purpose treatment. Start 2011-01-15 (actual); primary completion 2012-10-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ipragliflozin
Intervention (Drug)
nateglinide
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01316107
Content hash
e3e188049e45de23149dd376782930f15044a7c6d93599122e1711d9620b2de0